Vertex Pharmaceuticals (VX1d)
FRA • Healthcare
April 17, 2026 at 17:30 UTC
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company that discovers, develops, and supplies therapies for serious diseases addressed by targeted approaches. Research is organized around human biology and validated mechanisms, and programs move from early studies to practice with a focus on clear labeling and safe administration. Manufacturing is built for reproducible output and steady availability once a therapy enters routine care. Medical information and field support help clinicians apply guidance without breaking normal workflow. Regional teams manage access within local frameworks, while global functions keep quality and data safeguards aligned. In the healthcare sector and its partner ecosystem, the company positions itself as a long-term supplier that prioritizes continuity for providers and patients.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Vertex Pharmaceuticals's Technical Indicators Summary
VX1d is trading below its short- and long-term EMAs, with the MACD and raw momentum both signaling downside while RSI sits in the mid-40s, indicating limited bullish conviction. Volatility is moderate by recent standards and ATR shows a modest percent range, while ADX is very low, suggesting the current down-move lacks trend strength. On balance, volume-based OBV is not providing clear support and classic pivots sit above the market, reinforcing a cautious tone. Technical takeaway: Bearish—momentum and MACD are negative while trend strength remains weak.
| Indicator | Value |
|---|---|
RSI (14) | 44.30 |
Stochastic %K (14, 3, 3) | — |
CCI (20) | — |
WPR (14) | — |
Momentum (10) | -11.65 |
MFI | 39.26 |
MACD Level (12, 26) | -7.42 |
Bollinger Bands | — |
ATR (14) | $6.59 (1.78%) |
ADX (14) | 8.21 |
OBV | -36,445 |
Classic Pivot Point | $374.88 |
Fibonacci Pivot Point | $374.88 |
Exponential Moving Averages | $375.86 - $389.39(5 indicators) |
Simple Moving Averages | —(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
The session wrapped with VX1d mildly under yesterday, as the -0.28% gap down left it closing around 373.45. By the final tick, sector performance was mildly positive (1.47%), giving a light assist to the overall tone. VX1d closes slightly below yesterday as a small gap down weighs, while a broadly positive sector lends a light tailwind.
Price Change
from €373.45 close
-€2
Trading Volume
Below avg (64)
18
vs S&P 500 Today
Underperforming Market
-2.35%
52-Week Position
Mid-range
45.3%
Updated: April 17, 2026 at 15:10 UTC
Quote Summary
VX1d Headlines
Biotech ETFs Flash Classic Reversal Signal
April 1, 2026
Executives File New SEC Form 144 Sales
February 27, 2026